Zacks: Analysts Expect Radius Health, Inc. (NASDAQ:RDUS) Will Post Quarterly Sales of $59.75 Million


Share on StockTwits

Equities analysts expect Radius Health, Inc. (NASDAQ:RDUS) to post $59.75 million in sales for the current quarter, Zacks reports. Five analysts have made estimates for Radius Health’s earnings. The highest sales estimate is $62.12 million and the lowest is $59.00 million. Radius Health reported sales of $55.67 million during the same quarter last year, which indicates a positive year over year growth rate of 7.3%. The firm is expected to report its next earnings report before the market opens on Thursday, February 25th.

On average, analysts expect that Radius Health will report full-year sales of $235.94 million for the current financial year, with estimates ranging from $234.86 million to $237.98 million. For the next year, analysts anticipate that the company will post sales of $265.21 million, with estimates ranging from $256.50 million to $278.26 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Radius Health.

A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Radius Health from a “sell” rating to a “buy” rating and set a $19.00 target price for the company in a report on Monday, January 11th. HC Wainwright reiterated a “hold” rating on shares of Radius Health in a report on Thursday, January 7th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell boosted their target price on Radius Health from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, January 7th. Smith Barney Citigroup upped their price target on Radius Health from $25.00 to $30.00 in a report on Thursday, January 7th. Finally, SVB Leerink upped their price target on Radius Health from $17.00 to $20.00 and gave the stock a “market perform” rating in a report on Thursday, January 7th. Six equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $22.60.

RDUS traded up $0.02 during midday trading on Thursday, hitting $18.62. The company’s stock had a trading volume of 21,677 shares, compared to its average volume of 442,362. Radius Health has a 52-week low of $10.15 and a 52-week high of $23.84. The firm has a market cap of $866.71 million, a P/E ratio of -7.62 and a beta of 1.18. The firm has a 50-day moving average price of $20.90 and a two-hundred day moving average price of $15.67.

Institutional investors and hedge funds have recently made changes to their positions in the business. Weld Capital Management LLC acquired a new position in shares of Radius Health in the 3rd quarter valued at approximately $122,000. Candriam Luxembourg S.C.A. raised its position in shares of Radius Health by 13.0% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 352,567 shares of the biopharmaceutical company’s stock valued at $6,296,000 after purchasing an additional 40,542 shares in the last quarter. Jupiter Asset Management Ltd. raised its position in shares of Radius Health by 90.2% in the 4th quarter. Jupiter Asset Management Ltd. now owns 324,326 shares of the biopharmaceutical company’s stock valued at $5,789,000 after purchasing an additional 153,837 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Radius Health by 10.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 443,241 shares of the biopharmaceutical company’s stock valued at $5,027,000 after purchasing an additional 43,276 shares in the last quarter. Finally, Jackson Creek Investment Advisors LLC acquired a new position in shares of Radius Health in the 4th quarter valued at approximately $1,097,000.

About Radius Health

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS, an anabolic agent for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in phase 3 clinical study for the treatment of osteoporosis in men; abaloparatide transdermal patch, a short-wear-time patch, that is in phase 3 clinical study to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in phase 3 clinical study for the treatment of hormone receptor-positive breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator, which is in phase 1A clinical study to treat metastatic breast cancer.

Further Reading: S&P/TSX Index

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.